Knight Therapeutics Inc Has Another Very Strong Trading Session

 Knight Therapeutics Inc Has Another Very Strong Trading Session

The stock of Knight Therapeutics Inc (TSE:GUD) is a huge mover today! About 33,105 shares traded hands. Knight Therapeutics Inc (TSE:GUD) has risen 21.26% since April 8, 2016 and is uptrending. It has outperformed by 16.28% the S&P500.
The move comes after 5 months positive chart setup for the $1.31 billion company. It was reported on Nov, 14 by We have $15.89 PT which if reached, will make TSE:GUD worth $851.50M more.

Knight Therapeutics Inc (TSE:GUD) Ratings Coverage

Out of 2 analysts covering Knight Therapeutics (TSE:GUD), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $11 is the highest target while $9.50 is the lowest. The $10.27 average target is 6.65% above today’s ($9.63) stock price. Knight Therapeutics has been the topic of 5 analyst reports since May 12, 2016 according to StockzIntelligence Inc.

More important recent Knight Therapeutics Inc (TSE:GUD) news were published by: which released: “Exclusive: Endo considers sale of Paladin Labs to Knight Therapeutics – so…” on November 04, 2016, also published article titled: “How Many Times Can Knight Therapeutics Issue Equity?”, published: “Put Knight Therapeutics On Your Watchlist” on April 01, 2016. More interesting news about Knight Therapeutics Inc (TSE:GUD) was released by: and their article: “Braeburn Pharmaceuticals and Knight Therapeutics Announce Canadian Sublicense …” with publication date: February 01, 2016.

Knight Therapeutics Inc is a Canada pharmaceutical company. The company has a market cap of $1.31 billion. The Firm is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets. It has a 59.17 P/E ratio. It finances other life sciences companies in Canada and internationally.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment